Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Ms. Yue Wang United States

Single cell multi-omics company to eradicate cancer
Website:
Missionbio.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
To expand user base and market
Headquartner in China
No
MissionBio
Fas 
Functionality
Sales and Marketing

Yuqi Wang China

QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
Website:
www.parkinsons-disease-care.mysxl.cn
Partnering Objectives
Headquartner in China
Yes
QiRun Biotech
Founder 

bingwen wang United States

Top American medical device company
Website:
bostonscientific.cn
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Boston Scientific
physician 

Cynthia Wang China

.
Website:
www.Servier.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Assets based licensing in
Headquartner in China
No
Servier
BD&Licensing Director 

Ms. Danni Wang China

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.
Website:
www.harbourbiomed.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Licensing-out and Licensing-in of targeted therapeutic areas
Headquartner in China
Yes
Harbour BioMed
Senior Director, Business Development 
Functionality
Business Development

Dr. Duan Wang China

Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Website:
http://www.hrs.com.cn/
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Looking for Assets to in license and global partners
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
SHR-1701|SHR-1701is an anti-PD-L1/TGF-βRII bi-functional fusion protein that inhibits PD-L1 andTGF-β. It is currently under phase II and phase I clinical development in China and Australia, respectively. Preliminary data from SHR-1701’s two phase I trials showed promising efficacy and safety.|Solid tumor|
Assets Information 2
Pyrotinib|Pyrotinib is a novel selective tyrosine kinase inhibitor of EGFR/HER2/HER4, with superior efficacy vs. lapatinib. Global registrational trial ongoing; approved in China.|HER2-positive breast cancer|
Assets Information 3
Fluzoparib|Fluzoparib is a PARP inhibitor to address ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other advanced solid tumors.|Solid tumor|
Biotech/Pharma Asset Stage
Jiangsu Hengrui Pharma
Associate Director of BD 
Functionality
Business Development

Yung-Chih Wang United States

Website:
www.huyabio.com
Partnering Objectives
Please specify your partnering goal
To find new projects of interest
Headquartner in China
No
Biotech/Pharma Category
HUYA BIOSCIENCE INTERNATIONAL
Senior Vice President, Corporate Development China 

Jonathan Wang

Inmagene Biopharmaceuticals
Chairman and CEO 

Ms Luyao Wang China

Website:
www.jacobiopharma.com
Company Size (Fulltime employees)
51-200
Year of foundation
5
Biotech/Pharma Category
Jacobio Pharmaceuticals
Director of PR 
Functionality
Other

William Wang China

see company website
Website:
www.tiandapharma.com
Partnering Objectives
Headquartner in China
Yes
Tianda Pharmaceutical Ltd.
CEO